This document outlines a study that aims to compare the effectiveness of clinical studies versus pharmacology trial studies in diagnosing Alzheimer's disease. It also seeks to determine if people under 65 with cardiovascular conditions are more likely to develop Alzheimer's. The proposed methodology involves two clinical study groups of 100 people aged 45-65 and four pharmacology trial groups of 25 people each, half with and half without cardiovascular histories. The study expects that trial studies will more efficiently diagnose Alzheimer's and that those with cardiovascular conditions will be more likely to develop early-onset Alzheimer's. The goals are to influence diagnosis methods and develop new early-intervention treatments.

1. ALZHEIMER’S DISEASE
CLINICAL OR TRIAL ?

2. ALZHEIMER’S DISEASE
 Is a type of dementia that causes dangerous and
radical problems in a person’s way of
thinking, memory, and behavior
 Dementia is the general term used to describe
memory loss and other intellectual abilities that
negatively affects a patient’s daily life

3. PROBLEM
 Are pharmacology trial based studies more efficient
than common clinical studies on the diagnosis of
Alzheimer’s disease ?
 Does having any cardiovascular condition directly
affects the possibility of a person under the age of
65 to develop Alzheimer’s disease in the future ?

4. HYPOTHESIS
 Trial research based on pharmacology experiments
will be the best way to diagnose and treat
Alzheimer’s disease
 People with cardiovascular conditions will have
more possibilities of suffering Alzheimer’s disease
than does who do not

5. OBJECTIVES
 To take advantage of my experiment’s results for a
better understanding of the disease
 To prove that “trial studies” are the best way to
recognize and diagnose Alzheimer’s disease
 To prove people with cardiovascular conditions are
more likely to develop Alzheimer before the age of
65 years old

6. METHODOLOGY
 Clinical studies will consist of 2 groups of people
within the ages of 45 to 65 years old
 Each group will consist of 100 members
 Pharmacology Trials
 Four groups of 25 members
 One half will have cardiovascular condition history
 One half will not
 Experimental drugs will be considered on this research

7. PATIENT’S CONSENT
 Each participant of the Pharmacology Trial study
must sign an informed consent
agreement, affirming that he or she is willing to
participate, and understands the study and its
purpose.

8. EXPECTED RESULTS
 Trial research will be more efficient than Clinical
studies to diagnose Alzheimer’s disease
 Patients with a history of cardiovascular conditions
will be more likely to suffer Alzheimer’s disease
under the age of 65

9. LONG TERM GOALS
 To drastically influence the way Alzheimer’s disease
is diagnosed
 To develop new treatments based on premature
intervention that would save a patient’s life

10. REFERENCES
 Alzheimer's Association. 2012 Alzheimer's disease
facts and figures. Alzheimer's and Dementia: The
Journal of the Alzheimer's Association. March 2012;
8:131–168.
http://www.alz.org/alzheimers_disease_facts_and_fi
gures.asp

11. QUESTIONS ?